Home » Advisor » David Ridley

Category Archives: David Ridley

Impact of Medicare Advantage Supplemental Benefit Expansion on Startup Funding

by Judy Tianhong Zhong Abstract  In 2018, the Center for Medicare and Medicaid Services (CMS) announced that they would expand the supplemental benefits that can be included in Medicare Advantage (MA) plans. The goal was to encourage insurers to innovate and test new benefit offerings that could improve health outcomes and reduce healthcare spending. A […]

Continue Reading →

Incentive Programs for Neglected Diseases

By Pranav Ganapathy    We propose and evaluate an auction mechanism for the priority review voucher program. The 2007 voucher program rewards drug developers for regulatory approval of novel treatments for neglected tropical diseases. Previous papers have proposed auctioning vouchers for the priority review voucher program but have offered neither a mathematical model nor a […]

Continue Reading →

Competition and Innovation: Evidence from Third-Party Reprocessing in the Medical Device Industry

By Varun Prasad    Healthcare is projected to soon become the industry with the largest amount of spending on research and development in the world. While competition has the potential to catalyze the development of new healthcare technologies and drive down costs, increases in competition have also been thought to hinder innovation as a result […]

Continue Reading →

Federal and Industrial Funded Research Expenditures and University Technology Transfer licensing

By Trent Chiang In this paper I relate the numbers of university licenses and options to both university research characteristics and research expenditures from federal government or industrial sources. I apply the polynomial distributed lag model for unbalanced panel data to understand the effects of research expenditures from different sources on licensing activity. We find […]

Continue Reading →

Price Discrimination and Bargaining Power in the Global Vaccine Market

By Linda Li Since the 1980’s, the market structure of vaccines has become increasingly oligopolistic, and in some cases monopolistic. Alongside these supply trends, we see the emergence and growth of group procurement schemes on the demand side of the market. National government and international organization procure vaccines on behalf of end users. Two such […]

Continue Reading →

Questions?

Undergraduate Program Assistant
Matthew Eggleston
dus_asst@econ.duke.edu

Director of the Honors Program
Michelle P. Connolly
michelle.connolly@duke.edu